Older HPV-Positive Oropharyngeal Cancer Patients Have High Treatment Tolerability

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video examines results of a study that looked at treatment tolerability in elderly patients with HPV-positive oropharyngeal squamous cell carcinoma.

In this video, Richard Bakst, MD, of the Icahn School of Medicine at Mount Sinai in New York, discusses a study that examined treatment tolerability and outcomes in elderly patients (65 years and older) with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.

Bakst presented the results of the study (abstract 2764) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Recent Videos
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content
The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

Tim Cortese
October 29th 2025
Article

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Data from the BL-B01D1-301 study support iza-bren as a potential standard of care for pretreated recurrent or metastatic nasopharyngeal carcinoma.

Iza-Bren Increases Responses in Recurrent Nasopharyngeal Carcinoma

Jonah Feldman
October 19th 2025
Article

Data from the BL-B01D1-301 study support iza-bren as a potential standard of care for pretreated recurrent or metastatic nasopharyngeal carcinoma.

The investigator-evaluated ORR was 39.0% among those treated for recurrent/metastatic HNSCC, and the CR and PR rates were 9.8% and 29.3%, respectively.

Enfortumab Vedotin/Pembrolizumab Display Frontline Efficacy in PD-L1+ HNSCC

Jax DiEugenio
October 19th 2025
Article

The investigator-evaluated ORR was 39.0% among those treated for recurrent/metastatic HNSCC, and the CR and PR rates were 9.8% and 29.3%, respectively.

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

Comprehensive Cancer Database May Enhance Personalized Therapy

Russ Conroy
October 15th 2025
Article

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

The full indication excludes patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.

Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Frontline HNSCC

Tim Cortese
October 14th 2025
Article

A median OS of 21.3 months was found in the phase 1/1b trial evaluating ficerafusp alfa plus pembrolizumab in those with metastatic and recurrent HNSCC.